Literature DB >> 21914639

Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance.

Daniela Kuhnt1, Andreas Becker, Oliver Ganslandt, Miriam Bauer, Michael Buchfelder, Christopher Nimsky.   

Abstract

Extent of resection (EOR) still remains controversial in therapy of glioblastoma multiforme (GBM). However, an increasing number of studies favor maximum EOR as being associated with longer patient survival. One hundred thirty-five GBM patients underwent tumor resection aided by 1.5T intraoperative MRI (iMRI) and integrated multimodal navigation. Tumor volume was quantified by manual segmentation. The influences of EOR, patient age, recurrent tumor, tumor localization, and gender on survival time were examined. Intraoperative MRI detected residual tumor volume in 88 patients. In 19 patients surgery was continued; further resection resulted in final gross total resection (GTR) for 9 patients (GTR increased from 47 [34.80%] to 56 [41.49%] patients). Tumor volumes were significantly reduced from 34.25 ± 23.68% (first iMRI) to 1.22 ± 16.24% (final iMRI). According to Kaplan-Meier estimates, median survival was 14 months (95% confidence interval [CI]: 11.7-16.2) for EOR ≥ 98% and 9 months (95% CI: 7.4-10.5) for EOR <98% (P< .0001); it was 9 months (95% CI: 7.3-10.7) for patients ≥ 65 years and 12 months (95% CI: 8.4-15.6) for patients <65 years (P < .05). Multivariate analysis showed a hazard ratio of 0.39 (95% CI: 0.24-0.63; P = .001) for EOR ≥ 98% and 0.61 (95% CI: 0.38-0.97; P < .05) for patient age <65 years. To our knowledge, this is the largest study including correlation of iMRI, tumor volumetry, and survival time. We demonstrate that navigation guidance and iMRI significantly contribute to optimal EOR with low postoperative morbidity, where EOR ≥ 98% and patient age <65 years are associated with significant survival advantages. Thus, maximum EOR should be the surgical goal in GBM surgery while preserving neurological function.

Entities:  

Mesh:

Year:  2011        PMID: 21914639      PMCID: PMC3223093          DOI: 10.1093/neuonc/nor133

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  36 in total

1.  Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.

Authors:  G Evren Keles; Edward F Chang; Kathleen R Lamborn; Tarik Tihan; Chih-Ju Chang; Susan M Chang; Mitchel S Berger
Journal:  J Neurosurg       Date:  2006-07       Impact factor: 5.115

2.  Advanced approach for intraoperative MRI guidance and potential benefit for neurosurgical applications.

Authors:  Harald Busse; Arno Schmitgen; Christos Trantakis; Ralf Schober; Thomas Kahn; Michael Moche
Journal:  J Magn Reson Imaging       Date:  2006-07       Impact factor: 4.813

Review 3.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

4.  Updating navigation with intraoperative image data.

Authors:  Christopher Nimsky; Boris von Keller; Sven Schlaffer; Daniela Kuhnt; Daniel Weigel; Oliver Ganslandt; Michael Buchfelder
Journal:  Top Magn Reson Imaging       Date:  2009-01

5.  Volumetric assessment of glioma removal by intraoperative high-field magnetic resonance imaging.

Authors:  Christopher Nimsky; Atsushi Fujita; Oliver Ganslandt; Boris Von Keller; Rudolf Fahlbusch
Journal:  Neurosurgery       Date:  2004-08       Impact factor: 4.654

6.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

7.  Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis.

Authors:  Mustafa Aziz Hatiboglu; Jeffrey S Weinberg; Dima Suki; Ganesh Rao; Sujit S Prabhu; Komal Shah; Ed Jackson; Raymond Sawaya
Journal:  Neurosurgery       Date:  2009-06       Impact factor: 4.654

8.  Integration of biochemical images of a tumor into frameless stereotaxy achieved using a magnetic resonance imaging/magnetic resonance spectroscopy hybrid data set.

Authors:  Andreas Stadlbauer; Ewald Moser; Stephan Gruber; Christopher Nimsky; Rudolf Fahlbusch; Oliver Ganslandt
Journal:  J Neurosurg       Date:  2004-08       Impact factor: 5.115

9.  Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients.

Authors:  G Evren Keles; David A Lundin; Kathleen R Lamborn; Edward F Chang; George Ojemann; Mitchel S Berger
Journal:  J Neurosurg       Date:  2004-03       Impact factor: 5.115

10.  Low field intraoperative MRI-guided surgery of gliomas: a single center experience.

Authors:  Christian Senft; Kea Franz; Christian T Ulrich; Andrea Bink; Andrea Szelényi; Thomas Gasser; Volker Seifert
Journal:  Clin Neurol Neurosurg       Date:  2009-12-24       Impact factor: 1.876

View more
  90 in total

1.  miR-128 regulates the apoptosis and proliferation of glioma cells by targeting RhoE.

Authors:  Chao Shang; Yang Hong; Yan Guo; Yun-Hui Liu; Yi-Xue Xue
Journal:  Oncol Lett       Date:  2015-11-17       Impact factor: 2.967

Review 2.  Fluorescein-guided surgery for malignant gliomas: a review.

Authors:  Francesco Acerbi; Claudio Cavallo; Morgan Broggi; Roberto Cordella; Elena Anghileri; Marica Eoli; Marco Schiariti; Giovanni Broggi; Paolo Ferroli
Journal:  Neurosurg Rev       Date:  2014-04-23       Impact factor: 3.042

3.  Impact of initial midline shift in glioblastoma on survival.

Authors:  Johannes Wach; Motaz Hamed; Patrick Schuss; Erdem Güresir; Ulrich Herrlinger; Hartmut Vatter; Matthias Schneider
Journal:  Neurosurg Rev       Date:  2020-06-04       Impact factor: 3.042

4.  Immediate post-operative MRI suggestive of the site and timing of glioblastoma recurrence after gross total resection: a retrospective longitudinal preliminary study.

Authors:  Thibault Smets; Tévi Morel Lawson; Cécile Grandin; Aleksandar Jankovski; Christian Raftopoulos
Journal:  Eur Radiol       Date:  2013-01-12       Impact factor: 5.315

Review 5.  Surgical management of high-grade glioma: a standard of care.

Authors:  Colin Watts
Journal:  CNS Oncol       Date:  2012-11

Review 6.  Neurosurgical oncology: advances in operative technologies and adjuncts.

Authors:  Randy S D'Amico; Benjamin C Kennedy; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2014-06-27       Impact factor: 4.130

7.  Benefit of tumor resection for recurrent glioblastoma.

Authors:  Johanna Quick; Florian Gessler; Stephan Dützmann; Elke Hattingen; Patrick N Harter; Lutz M Weise; Kea Franz; Volker Seifert; Christian Senft
Journal:  J Neurooncol       Date:  2014-02-15       Impact factor: 4.130

Review 8.  Glioblastoma: Overview of Disease and Treatment.

Authors:  Mary Elizabeth Davis
Journal:  Clin J Oncol Nurs       Date:  2016-10-01       Impact factor: 1.027

9.  Fiber tractography based on diffusion tensor imaging compared with high-angular-resolution diffusion imaging with compressed sensing: initial experience.

Authors:  Daniela Kuhnt; Miriam H A Bauer; Jan Egger; Mirco Richter; Tina Kapur; Jens Sommer; Dorit Merhof; Christopher Nimsky
Journal:  Neurosurgery       Date:  2013-01       Impact factor: 4.654

10.  Choline-to-N-acetyl aspartate and lipids-lactate-to-creatine ratios together with age assemble a significant Cox's proportional-hazards regression model for prediction of survival in high-grade gliomas.

Authors:  Ernesto Roldan-Valadez; Camilo Rios; Daniel Motola-Kuba; Juan Matus-Santos; Antonio R Villa; Sergio Moreno-Jimenez
Journal:  Br J Radiol       Date:  2016-09-14       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.